Document:

Consultation and Clinical Advisory Board Agreement with Bennett Shapiro

 Exhibit 10.17 
 ELIXIR PHARMACEUTICALS, INC. 
 CONSULTATION AND CLINICAL ADVISORY BOARD AGREEMENT 

This Consultation and Clinical Advisory Board Agreement (the “Agreement”), dated as of June 4, 2003 (the “Effective Date”),
is made between Elixir Pharmaceuticals, Inc., a Delaware corporation having a place of business at One Kendall Square, Building 1000 Fifth Floor, Cambridge, MA 02139 (the “Company”), and Bennett Shapiro (“Advisor”).

 INTRODUCTION 
 1. The Company
desires to have the benefit of the Advisors’ knowledge and experience in the development of its technology, and the Advisor desires to provide consulting services to the Company, all as provided in this Agreement. 
 2. The Company desires to have the Advisor serve as a member of the Company’s Clinical Advisory Board (the “CAB”), and the Advisor desires
to serve as a member of the CAB. 
 NOW, THEREFORE, in consideration of the promises and mutual agreements set forth in this Agreement, the
Company and the Advisor agree as follows: 
 1. Consultation and Clinical Advisory Board. The Company shall retain the Advisor as a
consultant, and the Advisor shall serve the Company as a consultant and a member of the CAB upon the terms and conditions set forth in this Agreement. However, the Advisor shall be engaged by the Company as a consultant for the exchange of ideas
only and shall not direct or conduct research for or on behalf of the Company. The Company and the Advisor acknowledge that the CAB is not a committee of the Company’s Board of Directors. 
 2. Term. Subject to the terms and conditions set forth in Section 5 below, the term of the Advisor’s consulting arrangement and service
on the CAB (hereinafter referred to as the “Consultation Period”) shall commence on the Effective Date and shall continue until the first anniversary of the Effective Date, unless extended by mutual agreement for additional one year
periods. 
 3. Consulting and CAB Duties. 
 3.1. During the Consultation Period, Advisor shall serve as a member of the CAB and shall provide to the Company such consulting services in his fields of expertise and knowledge related to the technologies and
business of the Company (the “Services”), including providing at least twelve (12) days of consulting and CAB service per year, which shall include attending at least four (4) meetings of the CAB. The Company shall give the
Advisor reasonable advance notice of any Services required of him hereunder. The number and frequency of meetings of the CAB to be held during the Consultation Period shall be determined at the Company’s sole discretion. 
 3.2. All work to be performed by the Advisor for the Company shall be under the general supervision of the Company. 

 3.3. The Advisor shall devote his best efforts and ability to the performance of the duties attaching to
this obligation. All work performed by the Advisor for the Company shall be at times reasonably convenient to the Advisor. 
 4.
Compensation. 
 4.1. Consulting Fees. The Company shall pay to the Advisor consulting fees of US$2,500 per CAB meeting attended
and US$1,500 per half day for services performed outside formal CAB meetings, payable in arrears on the last day of the month following the month in which services were rendered. Advisor shall calculate Consulting Fees for services performed outside
formal CAB meetings on a pro rata basis and shall invoice Company for fees owed to Advisor under this Section 4.1. 
 4.2. Stock
Options. Subject to the approval of the Board of Directors, the Company shall grant Advisor a nonstatutory option (the “Option”) to purchase twenty thousand (20,000) shares of the Company’s common stock, $0.001 par value per
share (“Common Stock”), pursuant to the Company’s 2001 Stock Incentive Plan (the “Plan”) at the then fair market value of the Company’s Common Stock as determined in good faith by the Company’s Board of Directors.
The Option shall become exercisable during the Consultation Period in accordance with the provisions of the Plan. 
 4.3. Reimbursement of
Expenses. The Company shall reimburse the Advisor for all reasonable and necessary expenses incurred or paid by the Advisor in connection with, or related to, the performance of his services under this Agreement. The Advisor shall submit to the
Company itemized statements, in a form satisfactory to the Company, of such expenses incurred by the Advisor. The Company shall pay to the Advisor the amounts shown on each such statement within 30 days after receipt thereof. Notwithstanding the
foregoing, the Advisor shall not incur total expenses in excess of US$1,000 per month without the prior written approval of the Company. 
 4.4. Benefits. The Advisor shall not be entitled to any benefits, coverages or privileges, including, without limitation, social security, unemployment, medical or pension payments, made available to employees of the Company.

 5. Termination. Either party may terminate the Consultation Period upon thirty (30) days prior written notice to the other
party. The Consultation Period shall also terminate automatically upon the death or disability of the Advisor. In the event of any such termination, the Advisor shall be entitled to payment for services performed and expenses paid or incurred prior
to the effective date of termination, subject to the limitation on reimbursement of expenses set forth in Section 4.3. Such payments shall constitute full settlement of any and all claims of the Advisor of every description against the Company,
other than the Advisor’s right to indemnification under Section 10 of this Agreement. In addition, any shares of restricted Common Stock issued pursuant to the Restricted Stock Agreement which have not vested as of the date of termination
shall be purchasable by the Company in accordance with the provisions set forth in the Restricted Stock Agreement. Notwithstanding the foregoing, the Company may terminate the Consultation Period, effective immediately upon receipt of written
notice, if the Advisor breaches or threatens to breach any provision of Section 6, 7, or 9. The following provisions shall survive termination of this Agreement: Sections 7, 9, 10 and 14. 
  

 - 2 - 

 6. Cooperation. The Advisor shall use his best efforts in the performance of his obligations under
this Agreement. The Company shall provide such access to its information and property as may be reasonably required in order to permit the Advisor to perform his obligations hereunder. The Advisor shall cooperate with the Company’s personnel,
shall not interfere with the conduct of the Company’s business and shall observe all rules, regulations and security requirements of the Company concerning the safety of persons and property. 
 7. Non-Disclosure and Developments. 
 7.1. Proprietary Information. 
 (a) The Advisor agrees that all information, whether or not in writing, of a private, secret
or confidential nature concerning the Company’s business, business relationships or financial affairs (collectively, “Proprietary Information”) is and shall be the exclusive property of the Company. By way of illustration, but not
limitation, Proprietary Information may include inventions, products, processes, methods, techniques, formulas, compositions, compounds, projects, developments, plans, research data, clinical data, financial data, personnel data, computer programs,
customer and supplier lists, and contacts at or knowledge of customers or prospective customers of the Company. The Advisor will not disclose any Proprietary Information to any person or entity other than employees of the Company or use the same for
any purposes (other than in the performance of his duties as an employee of the Company) without written approval by an officer of the Company, either during or after the Consultation Period, unless and until such Proprietary Information has become
public knowledge without fault by the Advisor. The Advisor agrees that all files, letters, memoranda, reports, records, data, sketches, drawings, laboratory notebooks, program listings, or other written, photographic, or other tangible material
containing Proprietary Information, whether created by the Advisor or others, which shall come into his custody or possession, shall be and are the exclusive property of the Company to be used by the Advisor only in the performance of his duties for
the Company. All such materials or copies thereof and all tangible property of the Company in the custody or possession of the Advisor shall be delivered to the Company, upon the earlier of (i) a request by the Company or (ii) termination
of this Agreement. After such delivery, the Advisor shall not retain any such materials or copies thereof or any such tangible property. 
 (b) The Advisor agrees that his/her obligation not to disclose or to use information and materials of the types set forth in paragraphs (a) and (b) above, and his obligation to return materials and tangible property, set forth in
paragraph (b) above, also extends to such types of information, materials and tangible property of customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to the
Advisor. 
 7.2. Developments. 
 (a) The Advisor will make full and prompt disclosure to the Company of all inventions, improvements, discoveries, methods, developments, software, and works of authorship, whether patentable or not, which are created, made, conceived or
reduced to practice by him/her or under his/her direction or jointly with others during the Consultation Period, whether or not during normal working hours or on the premises of the Company, which relate 

  

 - 3 - 

 
directly or indirectly, to the business of the Company AND arise out of Advisor’s consulting relationship with the Company (all of which are
collectively referred to in this Agreement as “Developments”). 
 (b) The Advisor agrees to assign and does hereby assign to the
Company (or any person or entity designated by the Company) all his right, title and interest in and to all Developments and all related patents, patent applications, copyrights and copyright applications. However, this paragraph 7.2(b) shall not
apply to Developments which do not relate to the present or planned business or research and development of the Company and which are made and conceived by the Advisor not during normal working hours, not on the Company’s premises and not using
the Company’s tools, devices, equipment or Proprietary Information. The Advisor understands that, to the extent this Agreement shall be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to
assign certain classes of inventions made by an employee, this paragraph 7.2(b) shall be interpreted not to apply to any invention which a court rules and/or the Company agrees falls within such classes. The Advisor also hereby waives all claims to
moral rights in any Developments. 
 (c) The Advisor agrees to cooperate fully with the Company, both during and after the Consultation
Period, with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States and foreign countries) relating to Developments. The Advisor shall sign all papers,
including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable in order to protect its
rights and interests in any Development. The Advisor further agrees that if the Company is unable, after reasonable effort, to secure the signature of the Advisor on any such papers, any executive officer of the Company shall be entitled to execute
any such papers as the agent and the attorney-in-fact of the Advisor, and the Advisor hereby irrevocably designates and appoints each executive officer of the Company as his agent and attorney-in-fact to execute any such papers on his behalf, and to
take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Development, under the conditions described in this sentence. 
 7.3. Other Agreements. The Advisor hereby represents that, except as the Advisor has disclosed in writing to the Company in Schedule A, the
Advisor is not bound by the terms of any agreement with any previous or current employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of the Consultation Period, to
refrain from competing, directly or indirectly, with the business of such previous or current employer or any other party or to refrain from soliciting employees, customers or suppliers of such previous employer or other party. The Advisor further
represents that his performance of all the terms of this Agreement and the performance of his duties as a consultant of the Company do not and will not breach any agreement with any prior or current employer or other party to which the Advisor is a
party (including without limitation any nondisclosure or non-competition agreement), and that the Advisor will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous
or current employer or others. 
  

 - 4 - 

 7.4. United States Government Obligations. The Advisor acknowledges that the Company from time to
time may have agreements with other persons or with the United States Government, or agencies thereof, which impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the
confidential nature of such work. The Advisor agrees to be bound by all such obligations and restrictions which are made known to the Advisor and to take ail action necessary to discharge the obligations of the Company under such agreements.

 7.5. Remedies. The Advisor acknowledges that any breach of the provisions of this Section 7 shall result in serious and
irreparable injury to the Company for which the Company cannot be adequately compensated by monetary damages alone. The Advisor agrees, therefore, that, in addition to any other remedy it may have, the Company shall be entitled to enforce the
specific performance of this Agreement by the Advisor and to seek both temporary and permanent injunctive relief (to the extent permitted by law) without the necessity of proving actual damages. 
 8. Independent Contractor Status. The Advisor shall perform all services under this Agreement as an “independent contractor” and not as
an employee or agent of the Company. The Advisor is not authorized to assume or create any obligation or responsibility, express or implied, on behalf of, or in the name of, the Company or to bind the Company in any manner. 
 9. No Conflict of Interest; Non-Competition Agreement. The Advisor represents and warrants to the Company that he currently has no agreement with,
nor any other obligation to, any third party that would conflict with the terms of this Agreement, nor shall the Advisor enter into any such agreement nor incur such an obligation without the prior written consent of the Company. The Advisor further
represents that the performance of the Services will not breach any agreement or obligation with any third party, including without limitation any obligation to refrain from engaging in activities that may compete with such party. The Advisor
understands the confidential nature of the information and materials he will acquire or develop in performing his services under this Agreement. The Advisor acknowledges that if such information or materials were revealed to competitors of the
Company, then such disclosure could cause damage to the Company. Therefore, for the duration of the Consultation Period and for two (2) years thereafter, the Advisor shall not engage in any activities that would compete with the
Company—including without limitation becoming employed by, serving as a consultant for, serving as a member of a scientific or clinical advisory board (or a comparable organization) for, or acting in any manner on behalf of any other for-profit
enterprise that conducts activities similar to or competitive with those of the Company, without first obtaining the written consent of the Company. The Company agrees not to unreasonably withhold or delay its consent to activities by the Advisor in
areas with respect to which the Company either has no business activities or does not intend to develop business activities. 
 10.
Indemnification. With regard to the services to be performed by the Advisor pursuant to the terms of this Agreement, the Advisor shall not be liable to the Company, or to anyone who may claim any right due to his relationship with the
Company, for any acts or omissions in the performance of said services on the part of the Advisor or on the part of the agents or employees or contractors of the Advisor, except when said acts or omissions of the Advisor or agents, employees, of
contractors of the Advisor are due to their willful misconduct of gross negligence. The company shall hold the Advisor and its agents, employees, or 

  

 - 5 - 

 
contractors (each an “indemnified person”) free and harmless from any obligations, costs, claims, judgments, attorney fees and disbursements, and
attachments arising from or growing out of the services rendered to the Company pursuant to the terms of this Agreement or in any way connected with the rendering of said services, except when the same shall arise solely due to the willful
misconduct or gross negligence of the indemnified person as finally judicially determined by a court of competent jurisdiction. The Company agrees that the indemnification and reimbursement commitment set forth in this Agreement shall apply whether
or not the indemnified person is a formal party to any such lawsuits or other proceeding, that the indemnified person is entitled to retain separate counsel of its choice in connection with any of the matter to which such indemnification relates and
such indemnification shall survive any termination of this Agreement. The company further agrees that it will not, without the prior written consent of the indemnified person, settle, compromise or consent to the entry of any judgment in any pending
or threatened claim in respect of which indemnification may be sought hereunder (whether or not the indemnified person is an actual or potential party to such claim), if such settlement, compromise or consent includes any injunctive relief against
the indemnified person. 
 11. Notices. All notices required or permitted under this Agreement shall be in writing and shall be deemed
effective upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party at the address shown above, or at such other address or addresses as either party shall
designate to the other in accordance with this Section 11. 
 12. Pronouns. Whenever the context may require, any pronouns used
in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 
 13. Entire Agreement. This Agreement constitutes the entire agreement between the parties and supersedes all prior agreements and understandings,
whether written or oral, relating to the subject matter of this Agreement. 
 14. Amendment. This Agreement may be amended or modified
only by a written instrument executed by both the Company and the Advisor. 
 15. Governing Law. This Agreement shall be construed,
interpreted and enforced in accordance with the laws of the Commonwealth of Massachusetts. 
 16. Successors and Assigns. This
Agreement shall be binding upon, and inure to the benefit of, both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to its assets or business,
provided, however, that the obligations of the Advisor are personal and shall not be assigned by him. 
  

 - 6 - 

 17. Miscellaneous. 
 17.1. No delay or omission by the Company or the Advisor in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company or the Advisor on
any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion. 
 17.2. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. 
 17.3. In the event that any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability
of the remaining provisions shall in no way be affected or impaired thereby. 
 17.4. The Advisor represents that it has the competence
required to perform in a professional manner the services contemplated herein. The company understands and acknowledges that the Advisor has made no express or implied warranties apart from this Agreement. 
 17.5. The Company agrees to cooperate with the Advisor on all reasonable requests made by the Advisor including, without limitation, allowing the Advisor
reasonable access to the Company’s place of business, staff members, books and records to permit the Advisor to perform its services as fully and economically as possible. The Advisor may not be held liable for non-performance where the Advisor
is unable to perform, or performance is delayed, due to circumstances beyond the Advisor’s control including those caused by the Company. 
 17.6. Advisor’s Social Security Number: ###-##-#### 
 18. Notices. Payments, notices, or other communications
required by this Agreement shall be sufficiently made or given if mailed by certified mail, postage pre-paid, addressed to the address stated below, or to the last address specified in writing by the intended recipient, or by commercial carrier
(e.g., Airborne, Federal Express, etc.) when such carrier maintains certification of delivered mail. 
  

			
	 (a) If to Advisor:
	  	 Bennett Shapiro
 121 Greene Street #4
 New York, NY 10012

		
	 (b) If to Company:
	  	  
 CBO
 Elixir Pharmaceuticals, Inc.
 One Kendall Sq., Bldg 1000
 Cambridge, MA 02139
 Phone: (617) 995-7000
 Fax: (617) 995-7050

  

 - 7 - 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set forth
above. 
  

			
	ELIXIR PHARMACEUTICALS, INC.
	
	 /s/ Bard J. Geesaman

	By:	 	Bard J. Geesaman
	Title:	 	VP, Medical Development
	
	ADVISOR
	
	 /s/ Bennett Shapiro

	By:	 	Bennett Shapiro

  

 - 8 - 

 Schedule A 
 Advisor’s Agreements 
  

 - 9 - 

 

 
  

			
	

	 	November 12, 2004
	 	  
 Bennett M. Shapiro, M.D.

	 	Suite 524
	 	532 LaGuardia Place
		 	New York, NY 10012
		 	  
 Dear Ben:

		 	  
 Thank you for having been a part of Elixir. We appreciate all of the valuable
input you have given us.

		 	  
 Informally and verbally we have extended the CONSULTATION AND CLINICAL
ADVISORY BOARD AGREEMENT, however, the agreement expired on June 4, 2004. We certainly wish for you to continue your advisory role with us. In accordance with Section 2 of the Agreement, we would like for formally extend the term for another year
from the Effective Date, ending June 4, 2005.

		 	  
 Please sign and return one copy and keep the other for your records as an
amendment to the AGREEMENT.

									
					
		 	Sincerely,	 		 		 	
					
		 	 /s/ Bard Geesaman
	 		 		 	
		 	Bard Geesaman	 		 	
		 	Vice President, Medical Development	 		 	
					
		 		 		 	Signed:	 	 /s/ Bennett M. Shapiro

		 		 		 		 	Bennett M. Shapiro, M.D.
					
		 		 		 	Date:	 	[Illegible]
					
		 	Elixir Pharmaceuticals, Inc.	 	One Kendall Square	 		 	Tel 617.995.7000
		 	 www.elixirpharm.com
	 	Building 1000, Fifth Floor	 		 	Fax 617.995.7050
		 		 	Cambridge, MA 02139	 		 	

 

 
  

			
	

	 	November 7, 2005
	 	  
 Bennett M. Shapiro, M.D.

	 	Suite 524
	 	532 LaGuardia Place
		 	New York, NY 10012

 Dear Ben: 
 Thank you for having been a part of Elixir. We appreciate all the valuable input you have given us and look forward to continuing to work with you. 
 Informally and verbally we have extended the CONSULTATION AND CLINICAL ADVISORY BOARD AGREEMENT, however, the written agreement expired on June 4, 2005.
We certainly wish for you to continue your advisory role with us. In accordance with Section 2 of the AGREEMENT, we would like to formally extend the term for another year from the Effective Date, ending on June 4, 2006. 
 Please sign and return one copy and keep the other for your records as an amendment to the AGREEMENT. 
  

									
		 	Sincerely,	 		 		 	
					
		 	 /s/ Bard Geesaman
	 		 		 	
		 	Bard Geesaman	 		 		 	
		 	Vice President, Medical Development	 		 	
		 		 		 	Signed:	 	 /s/ Bennett M. Shapiro

		 		 		 		 	Bennett M. Shapiro, M.D.
					
		 		 		 	 Date:
	 	[Illegible]
					
		 	Elixir Pharmaceuticals, Inc.	 	One Kendall Square	 		 	Tel 617.995.7000
		 	www.elixirpharm.com	 	Building 1000, Fifth Floor	 		 	Fax 617.995.7050
		 		 	Cambridge, MA 02139	 		 	

 

 
  

			
	

	 	July 27, 2006
	 	  
 Bennett M. Shapiro, M.D.

	 	Suite 524
	 	532 LaGuardia Place
		 	New York, NY 10012
		 	  
 Dear Ben:

		 	  
 Thank you for having been a part of Elixir. We appreciate all the valuable
input you have given us and we look forward to continuing to work with you.

		 	  
 The CONSULTATION AND CLINICAL ADVISORY BOARD AGREEMENT expired on June 4,
2006. We certainly wish for you to continue your advisory role with us. In accordance with Section 2 of the AGREEMENT, we would like to extend the term for another year from the Effective Date, ending on June 4, 2007.

		 	  
 Please sign and return one copy and keep the other for your records as an
amendment to the AGREEMENT.

									
					
		 	Sincerely,	 		 		 	
					
		 	 /s/ Alan Watson
	 		 		 	
		 	Alan Watson	 		 	
		 	Executive Vice President & Chief Business Officer	 		 	
					
		 		 		 	Signed:	 	 /s/ Bennett M. Shapiro

		 		 		 		 	Bennett M. Shapiro, M.D.
					
		 		 		 	Date:	 	[Illegible]
					
		 	Elixir Pharmaceuticals, Inc.	 	One Kendall Square	 		 	Tel 617.995.7000
		 	 www.elixirpharm.com
	 	Building 1000, Fifth Floor	 		 	Fax 617.995.7050
		 		 	Cambridge, MA 02139	 		 	

 

 
  

			
	

	 	June 11, 2007
	 	  
 Bennett M. Shapiro, M.D.

	 	Suite 524
	 	532 LaGuardia Place
		 	New York, NY 10012

 Dear Ben: 
 Thank you for having been a part of Elixir. We appreciate all the valuable input you have given us and we look forward to continuing to work with you. 
 The CONSULTATION AND CLINICAL ADVISORY BOARD AGREEMENT expired on June 4, 2006. We certainly wish for you to continue your advisory role with us. In
accordance with Section 2 of the AGREEMENT, we would like to extend the term for two years from the Effective Date, ending on June 4, 2009. 
 Please sign and return one copy and keep the other for your records as an amendment to the AGREEMENT. 
  

									
		 	Sincerely,	 		 		 	
					
		 	 /s/ Alan Watson
	 		 		 	
		 	Alan Watson	 		 		 	
		 	Executive Vice President & Chief Business Officer	 		 	
					
		 		 		 	Signed:	 	 /s/ Bennett M. Shapiro

		 		 		 		 	Bennett M. Shapiro, M.D.
					
		 		 		 	Date:	 	19 June 02
					
		 	Elixir Pharmaceuticals, Inc.	 	12 Emily Street	 		 	Tel 617.995.7000
		 	www.elixirpharm.com	 	Cambridge, MA 02139	 		 	Fax 617.995.7050Consulting Agreement with Bennett Shapiro

 Exhibit 10.18 
 ELIXIR PHARMACEUTICALS, INC. 
 CONSULTING AGREEMENT 
 THIS CONSULTING AGREEMENT (“Agreement”) dated October 1, 2006 (the “Effective Date”) is made between Elixir
Pharmaceuticals, Inc. (the “Company”), with an office at One Kendall Square, Cambridge, MA 02139 and Bennett Shapiro, M.D. (the “Consultant”) of P.O. Box 777, 2632 North River Road, New Hope, PA 18938 for the purpose of setting
forth the exclusive terms and conditions by which Company desires to acquire Consultant’s services on a temporary basis. 
 In
consideration of the mutual obligations specified in this Agreement, the parties, intending to be legally bound hereby, agree to the following: 
 1. Services: 
 (a) Company hereby retains Consultant, and Consultant hereby agrees to perform for Company, certain
services (the “Services”) assigned to Consultant by the Company in the Company’s sole discretion for a minimum of one day per quarter including personal and telephonic meetings, document review and e-mail communications. These
Services are to be performed by Consultant only at the specific request of Company and are subject to the limits specified. 
 (b) Consultant
agrees to keep Company updated, promptly upon Company’s request, of any progress, problems, and/or developments of which Consultant is aware regarding the Services. 
 2. Compensation: 
 (a) In exchange for the full, prompt, and satisfactory performance of all
Services to be rendered to Company hereunder, Company shall provide Consultant, as full and complete compensation for the Services rendered hereunder a semi-annual fee of $7,500 plus reasonable out-of-pocket expenses. Company shall pay such
out-of-pocket expenses within thirty (30) days of receipt of expense receipts. 
 (b) Consultant shall not be entitled to receive any
other compensation or any benefits from Company. Except as otherwise required by law, Company shall not withhold any sums or payments made to Consultant for social security or other federal, state or local tax liabilities or contributions, and all
withholdings. liabilities, and contributions shall be solely Consultant’s responsibility. Company shall issue a Form 1099 to Consultant at the appropriate time. Further, Consultant understands and agrees that the Services are not covered under
the unemployment compensation laws and are not intended to be covered by workers’ compensation laws. 

 3. Nondisclosure: 
 (a) Consultant understands that, in connection with his engagement with Company, he may receive, produce, or otherwise be exposed to Company’s trade
secrets, business, proprietary and/or technical information, including, without limitation, business plans or projections, hardware and software designs or engineering techniques, software including listings, source code, screen formats and flow
charts, inventions (whether patentable or not), know-how, show-how, research plans and projects, pricing policies, cost information, supplier and customer lists and contracts, manufacturing techniques, applications and service policies, financial
and sales performance data, personnel information, and all derivatives, improvements and enhancements to any of the above (including those derivatives, improvements and enhancements that were created or developed by Consultant under this Agreement),
in addition to all information Company receives from others under an obligation of confidentiality (individually and collectively “Confidential Information”). Confidential Information shall also include all other information considered to
be confidential by the Company and all information which has not been made public. 
 (b) Consultant acknowledges that the Confidential
Information is the sole, exclusive and extremely valuable property of Company. Accordingly, Consultant agrees to segregate all Confidential Information from information of other companies and agrees not to reproduce any Confidential Information
without Company’s prior written consent, not to use the Confidential Information except in the performance of this Agreement, and not to divulge all or any part of the Confidential Information in any form to any third party, either during or
after the term of this Agreement. Upon termination or expiration of this Agreement for any reason, Consultant agrees to cease using and to return to Company all whole and partial copies and derivatives of the Confidential Information, whether in
Consultant’s possession or under Consultant’s direct or indirect control. 
 (c) Consultant shall not disclose or otherwise make
available to Company in any manner any confidential and proprietary information received by Consultant from third parties. Consultant warrants that his/her performance of all the terms of this Agreement does not and will not breach any agreement
entered into by Consultant with any other party, and Consultant agrees not to enter into any agreement, oral or written, in conflict herewith. In addition, Consultant recognizes that the Company has received and in the future will receive from third
parties their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality of such information and to use such information only for certain limited purposes. The Consultant agrees that he/she
owes the Company and such third parties, during the term of the Consultant’s relationship with the Company and thereafter, regardless for the reason for the termination of the relationship, a duty to hold all such confidential or proprietary
information in the strictest of confidence and not to disclose such information to any person, firm or corporation (except as necessary in carrying out his/her work for the Company consistent with the Company’s agreement with such third party)
or to use such information for the benefit of anyone other than for the Company or such third party (consistent with the Company’s agreement with such third party). 
  

 - 2 - 

 4. Ownership of Work Product: 
 (a) Consultant agrees to promptly disclose and assign to Company any and all Work Product. “Work Product” includes without limitation any and
all notes, drawings, designs, technical data, know how, works of authorship, firmware, software, ideas, improvements, inventions, material, information, work or product conceived, created, written or first reduced to practice by Consultant or
jointly with others in the performance of the Services under this Agreement and/or resulting from use of Confidential Information. Consultant agrees to assign and does hereby assign to Company all right, title and interest, including without
limitation any copyright, mask work, patent, trade secret, trademark (including the good will associated therewith) or other intellectual property rights in and to the Work Product. All works of authorship, firmware, software or other applicable
Work Product shall be considered works for hire by Consultant for Company and all Work Product shall be the sole and exclusive property of Company. Upon expiration or termination for any reason of this Agreement, Consultant agrees to and shall
provide Company with all Work Product generated under this Agreement. 
 (b) Consultant further agrees at the request and cost of the
Company: 
 (i) to apply for, obtain, register and vest in the name of the Company alone (unless the Company otherwise directs) patents,
copyrights, mask works, trademarks or other analogous protection in any country throughout the world and when so obtained or vested to renew and restore the same; and 
 (ii) to defend any judicial, opposition or other proceedings in respect of such applications and any judicial, opposition or other proceedings or petitions or applications for revocation of such patent, copyright,
mask work, trademark or other analogous protection. 
 (c) Consultant also agrees, at the request and cost of Company, to promptly sign,
execute, make and do all such deeds, documents, acts and things as Company may reasonably require or desire to perfect Company’s entire right, title, and interest in and to any Work Product and/or Background Material. Consultant agrees that if
Company is unable because of Consultant’s unavailability, dissolution, or for any other reason, to secure the signature of an authorized agent of Consultant to apply for or to pursue any application for any United States or foreign patents,
mask work, copyright or trademark registrations covering the assignments to Company above, then Consultant hereby irrevocably designates and appoints Company and its duly authorized officers and agents as Consultant’s agent and attorney in
fact, to act for and in Consultant’s behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of patents, copyright, mask work and trademark registrations
thereon with the same legal force and effect as if executed by an authorized agent of Consultant. 
 5. Indemnification/Release:
Consultant further agrees that any breach of Sections 3, 4 or 6 hereof by Consultant will cause irreparable harm to Company and that in the event of such breach or threatened breach, Company shall have, in addition to any and all remedies of law
and those remedies stated in this Agreement, the right to seek an injunction, specific performance 

  

 - 3 - 

 
or other equitable relief to prevent the violation of Consultant’s obligations hereunder. The Company recognizes that Consultant is providing advice to
the best of his ability and agres Consultant shall not be liable in any way for decisions which the company makes based on Consultant’s advice or counsel. The Company further agrees to indemnify Consultant against any and all legal proceedings
which may make reference to any advice or counsel that Consultant has provided to the Company in the course of carrying out Consultant’s obligations under this Agreement. 
 6. Termination: This Agreement shall be effective on the Effective Date hereof for a period of twelve (12) months, renewable annually
upon the mutual agreement of both parties. The agreement may be terminated by either party upon thirty (30) days written notice. In the event of termination, Consultant shall, upon request and at the company’s expense, perform such work as
may be requested to transfer work in process to the Company or to a party designated by the Company. The parties further agree that any termination of this Agreement will not release nor discharge Consultant from his or her obligations as specified
in Sections 3, 4, 5, 6, 7 or 8. 
 7. Independent Contractor: 
 (a) Company and Consultant expressly agree and understand that Consultant is an independent contractor and nothing in this Agreement nor the services
rendered hereunder is meant, or shall be construed in any way or manner, to create between them a relationship of employer and employee, principal and agent, partners or any other relationship other than that of independent parties contracting with
each other solely for the purpose of carrying out the provisions of the Agreement. Accordingly, Consultant acknowledges and agrees that Consultant shall not be entitled to any benefits provided by the Company to its employees. In addition,
Consultant shall have sole and exclusive responsibility for the payment of all federal, state and local income taxes, for all employment and disability insurance and for Social Security and other similar taxes with respect to any compensation
provided by the Company hereunder. Consultant shall assume and accept all responsibilities which are imposed on independent Consultants by any statute, regulation, rule of law, or otherwise. Consultant is not the agent of Company and is not
authorized and shall not have the power or authority to bind Company or incur any liability or obligation, or act on behalf of Company. At no time shall Consultant represent that he is an agent of the Company, or that any of the views, advice,
statements and/or information that may be provided while performing the Services are those of the Company. 
 (b) While Company is entitled
to provide Consultant with general guidance to assist Consultant in completing the scope of work to Company’s satisfaction, Consultant is ultimately responsible for directing and controlling the performance of the task and the scope of work, in
accordance with the terms and conditions of this Agreement. Consultant shall use his best efforts, energy and skill in his own name and in such manner as he sees fit. 
 8. General: 
 (a) This Agreement does not create an obligation on Company to continue to retain
Consultant beyond its term. This Agreement may not be changed unless mutually agreed upon in writing by both Consultant and Company. Sections 3, 4, 5, 6, 7 and 9 shall survive the 

  

 - 4 - 

 
termination of this Agreement regardless of the manner of such termination. Any waiver by Company of a breach of any provision of this Agreement shall not
operate or be construed as a waiver of any subsequent breach of such provision or any other provision hereof. 
 (b) Consultant hereby agrees
that each provision herein shall be treated as a separate and independent clause, and the unenforceability of any one clause shall in no way impair the enforceability of any of the other clauses herein. Moreover, if one or more of the provisions
contained in this Agreement shall for any reason be held to be excessively broad as to scope, activity, subject or otherwise so as to be unenforceable at law, such provision or provisions shall be construed by the appropriate judicial body by
limiting or reducing it or them, so as to be enforceable to the maximum extent compatible with the applicable law as it shall then appear. 
 (c) Company shall have the right to assign this Agreement to its successors and assigns and this Agreement shall inure to the benefit of and be enforceable by said successors or assigns. Consultant may not assign this Agreement or any
rights or obligations hereunder without the prior written consent of Company and this Agreement shall be binding upon Consultant’s heirs, executors, administrators and legal representatives. This Agreement and all aspects of the relationship
between the parties hereto shall be construed and enforced in accordance with and governed by the internal laws of the Commonwealth of Massachusetts without regard to its conflict of laws provisions. 
 (d) This Agreement contains the entire agreement between the parties hereto with respect to the transactions contemplated herein. All other negotiations
and agreements (written or oral) between the parties are superseded by this Agreement and there are no representations, warranties, understandings or agreements other than those expressly set forth herein. The language of all parts of this Agreement
will in all cases be construed as a whole in accordance with its fair meaning and not strictly for or against either party hereto. 
 (e) All
notices provided for in this Agreement shall be given in writing and shall be effective when either served by hand delivery, electronic facsimile transmission, express overnight courier service, or by registered or certified mail, return receipt
requested, addressed to the parties at their respective addresses as set forth at the beginning of this Agreement, or to such other address or addresses as either party may later specify by written notice to the other. 
 IN WITNESS WHEREOF, the parties hereto have executed this Independent Consultant Agreement. 
  

									
		 	BENNETT SHAPIRO, M.D.	 		 	ELIXIR PHARMACEUTICALS, INC.:
					
		 	 /s/ Bennett Shapiro
	 		 	By:	  	 /s/ Alan Watson

		 	Signature	 		 		  	
					
		 		 		 	Title:	  	CBO
					
		 	 [ILLEGIBLE]
	 		 		  	10/12/06
		 	Date	 		 	Date	  	

  

 - 5 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]